A Potential Link between Myeloperoxidase Modified LDL, Atherosclerosis and Depression
Abstract
:Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Libby, P.; Buring, J.E.; Badimon, L.; Hansson, G.K.; Deanfield, J.; Bittencourt, M.S.; Tokgözoğlu, L.; Lewis, E.F. Atherosclerosis. Nat. Rev. Dis. Primers 2019, 5, 56. [Google Scholar] [CrossRef] [PubMed]
- Delporte, C.; Van Antwerpen, P.; Vanhamme, L.; Roumeguère, T.; Zouaoui Boudjeltia, K. Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediat. Inflamm. 2013, 2013, 971579. [Google Scholar] [CrossRef] [PubMed]
- Daher, J. Other Forms of Oxidized LDL: Emerging Functions (Review). World Acad. Sci. J. 2020, 2, 4. [Google Scholar] [CrossRef]
- Vanhamme, L.; Zouaoui Boudjeltia, K.; Van Antwerpen, P.; Delporte, C. The other myeloperoxidase: Emerging functions. Arch. Biochem. Biophys. 2018, 649, 1–14. [Google Scholar] [CrossRef]
- Furtmüller, P.G.; Zederbauer, M.; Jantschko, W.; Helm, J.; Bogner, M.; Jakopitsch, C.; Obinger, C. Active site structure and catalytic mechanisms of human peroxidases. Arch. Biochem. Biophys. 2006, 445, 199–213. [Google Scholar] [CrossRef] [PubMed]
- Frangie, C.; Daher, J. Role of myeloperoxidase in inflammation and atherosclerosis (Review). Biomed. Rep. 2022, 16, 53. [Google Scholar] [CrossRef] [PubMed]
- Arnhold, J. The Dual Role of Myeloperoxidase in Immune Response. Int. J. Mol. Sci. 2020, 21, 8057. [Google Scholar] [CrossRef] [PubMed]
- Van der Veen, B.S.; de Winther, M.P.; Heeringa, P. Myeloperoxidase: Molecular mechanisms of action and their relevance to human health and disease. Antioxid. Redox Signal. 2009, 11, 2899–2937. [Google Scholar] [CrossRef] [PubMed]
- Aratani, Y. Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch. Biochem. Biophys. 2018, 640, 47–52. [Google Scholar] [CrossRef]
- Pan, X.L.; Nie, L.; Zhao, S.Y.; Zhang, X.B.; Zhang, S.; Su, Z.F. The Association Between Insomnia and Atherosclerosis: A Brief Report. Nat. Sci. Sleep 2022, 14, 443–448. [Google Scholar] [CrossRef]
- Chen, J.; Lin, S.; Zeng, Y. An Update on Obstructive Sleep Apnea for Atherosclerosis: Mechanism, Diagnosis, and Treatment. Front. Cardiovasc. Med. 2021, 8, 647071. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Cui, J.; Xu, B.; Wei, Y.; Fu, C.; Lv, X.; Xiong, L.; Qin, D. Sleep Disturbances and Depression Are Co-morbid Conditions: Insights From Animal Models, Especially Non-human Primate Model. Front. Psychiatry 2022, 12, 827541. [Google Scholar] [CrossRef] [PubMed]
- Daher, J.; Martin, M.; Rousseau, A.; Nuyens, V.; Fayyad-Kazan, H.; Van Antwerpen, P.; Courbebaisse, G.; Martiat, P.; Badran, B.; Dequiedt, F.; et al. Myeloperoxidase oxidized LDL interferes with endothelial cell motility through miR-22 and heme oxygenase 1 induction: Possible involvement in reendothelialization of vascular injuries. Mediat. Inflamm. 2014, 2014, 134635. [Google Scholar] [CrossRef] [PubMed]
- Bazzi, S.; Frangie, C.; Azar, E.; Daher, J. The effect of myeloperoxidase-oxidized LDL on THP-1 macrophage polarization and repolarization. Innate Immun. 2022, 28, 91–103. [Google Scholar] [CrossRef] [PubMed]
- Boudjeltia, K.Z.; Legssyer, I.; Van Antwerpen, P.; Kisoka, R.L.; Babar, S.; Moguilevsky, N.; Delree, P.; Ducobu, J.; Remacle, C.; Vanhaeverbeek, M.; et al. Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem. Cell Biol. 2006, 84, 805–812. [Google Scholar] [CrossRef] [PubMed]
- El-Hajjar, L.; Hindieh, J.; Andraos, R.; El-Sabban, M.; Daher, J. Myeloperoxidase-Oxidized LDL Activates Human Aortic Endothelial Cells through the LOX-1 Scavenger Receptor. Int. J. Mol. Sci. 2022, 23, 2837. [Google Scholar] [CrossRef] [PubMed]
- El-Hajjar, L.; Miranda, E.; El-Sabban, M.; Daher, J. Novel Insights into the Link Between Myeloperoxidase Modified LDL, LOX-1, and Neuroserpin in Stroke. Rev. Cardiovasc. Med. 2023, 24, 354. [Google Scholar] [CrossRef] [PubMed]
- Zouaoui Boudjeltia, K.; Guillaume, M.; Henuzet, C.; Delrée, P.; Cauchie, P.; Remacle, C.; Ducobu, J.; Vanhaeverbeek, M.; Brohée, D. Fibrinolysis and cardiovascular risk factors: Association with fibrinogen, lipids, and monocyte count. Eur. J. Intern. Med. 2006, 17, 102–108. [Google Scholar] [CrossRef] [PubMed]
- Zouaoui Boudjeltia, K.; Daher, J.; Van Antwerpen, P.; Moguilevsky, N.; Delree, P.; Ducobu, J.; Raes, M.; Badran, B.; Vanhaeverbeek, M.; Brohee, D.; et al. Exposure of endothelial cells to physiological levels of myeloperoxidase-modified LDL delays pericellular fibrinolysis. PLoS ONE 2012, 7, e38810. [Google Scholar] [CrossRef]
- El Samad, G.; Bazzi, S.; Karam, M.; Boudjeltia, K.Z.; Vanhamme, L.; Daher, J. Effect of myeloperoxidase modified LDL on bovine and human aortic endothelial cells. Exp. Ther. Med. 2019, 18, 4567–4574. [Google Scholar] [CrossRef]
- Zhang, Z.; Zhang, L.; Yepes, M.; Jiang, Q.; Li, Q.; Arniego, P.; Coleman, T.A.; Lawrence, D.A.; Chopp, M. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 2002, 106, 740–745. [Google Scholar] [CrossRef]
- Yepes, M.; Lawrence, D.A. Tissue-type plasminogen activator and neuroserpin: A well-balanced act in the nervous system? Trends Cardiovasc. Med. 2004, 14, 173–180. [Google Scholar] [CrossRef] [PubMed]
- Miranda, E.; Lomas, D.A. Neuroserpin: A serpin to think about. Cell. Mol. Life Sci. 2006, 63, 709–722. [Google Scholar] [CrossRef]
- Selkoe, D.J. Clearing the brain’s amyloid cobwebs. Neuron 2001, 32, 177–180. [Google Scholar] [CrossRef] [PubMed]
- Fabbro, S.; Seeds, N.W. Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. J. Neurochem. 2009, 109, 303–315. [Google Scholar] [CrossRef]
- Krystal, A.D. Psychiatric disorders and sleep. Neurol. Clin. 2012, 30, 1389–1413. [Google Scholar] [CrossRef]
- Krystal, A.D. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Med. Rev. 2009, 13, 265–274. [Google Scholar] [CrossRef] [PubMed]
- Thorpy, M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med. 2001, 2, 5–17. [Google Scholar] [CrossRef]
- van Leeuwen, W.M.; Lehto, M.; Karisola, P.; Lindholm, H.; Luukkonen, R.; Sallinen, M.; Härmä, M.; Porkka-Heiskanen, T.; Alenius, H. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS ONE 2009, 4, e4589. [Google Scholar] [CrossRef]
- Faraut, B.; Boudjeltia, K.Z.; Dyzma, M.; Rousseau, A.; David, E.; Stenuit, P.; Franck, T.; Van Antwerpen, P.; Vanhaeverbeek, M.; Kerkhofs, M. Benefits of napping and an extended duration of recovery sleep on alertness and immune cells after acute sleep restriction. Brain Behav. Immun. 2011, 25, 16–24. [Google Scholar] [CrossRef]
- Giedke, H.; Schwärzler, F. Therapeutic use of sleep deprivation in depression. Sleep Med. Rev. 2002, 6, 361–377. [Google Scholar] [CrossRef]
- Carney, C.E.; Segal, Z.V.; Edinger, J.D.; Krystal, A.D. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J. Clin. Psychiatry 2007, 68, 254–260. [Google Scholar] [CrossRef]
- Geoffroy, P.A.; Hoertel, N.; Etain, B.; Bellivier, F.; Delorme, R.; Limosin, F.; Peyre, H. Insomnia and hypersomnia in major depressive episode: Prevalence, sociodemographic characteristics and psychiatric comorbidity in a population-based study. J. Affect. Disord. 2018, 226, 132–141. [Google Scholar] [CrossRef] [PubMed]
- Muthuraman, K.; Sankaran, A.; Subramanian, K. Association Between Sleep-related Cognitions, Sleep-related Behaviors, and Insomnia in Patients with Anxiety and Depression: A Cross-sectional Study. Indian J. Psychol. Med. 2024, 46, 228–237. [Google Scholar] [CrossRef]
- Porter, G.A.; O’Connor, J.C. Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime? World J. Psychiatry 2022, 12, 77–97. [Google Scholar] [CrossRef]
- Piper, K.; Garelnabi, M. Eicosanoids: Atherosclerosis and cardiometabolic health. J. Clin. Transl. Endocrinol. 2020, 19, 100216. [Google Scholar] [CrossRef] [PubMed]
- Mashima, R.; Okuyama, T. The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol. 2015, 6, 297–310. [Google Scholar] [CrossRef]
- Wachsmann-Maga, A.; Maga, M.; Polczyk, R.; Włodarczyk, A.; Pasieka, P.; Terlecki, K.; Maga, P. Vascular Inflammatory Markers as Predictors of Peripheral Arterial Disease Patients’ Quality-of-Life Changes after Endovascular Treatment. J. Clin. Med. 2023, 12, 3412. [Google Scholar] [CrossRef] [PubMed]
- Dantzer, R.; O’Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9, 46–56. [Google Scholar] [CrossRef]
- Capuron, L.; Miller, A.H. Immune system to brain signaling: Neuropsychopharmacological implications. Pharmacol. Ther. 2011, 130, 226–238. [Google Scholar] [CrossRef]
- Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctôt, K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67, 446–457. [Google Scholar] [CrossRef] [PubMed]
- Köhler, C.A.; Freitas, T.H.; Maes, M.; de Andrade, N.Q.; Liu, C.S.; Fernandes, B.S.; Stubbs, B.; Solmi, M.; Veronese, N.; Herrmann, N.; et al. Peripheral cytokine and chemokine alterations in depression: A meta-analysis of 82 studies. Acta Psychiatr. Scand. 2017, 135, 373–387. [Google Scholar] [CrossRef] [PubMed]
- Dahl, J.; Ormstad, H.; Aass, H.C.; Malt, U.F.; Bendz, L.T.; Sandvik, L.; Brundin, L.; Andreassen, O.A. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 2014, 45, 77–86. [Google Scholar] [CrossRef] [PubMed]
- Hannestad, J.; DellaGioia, N.; Bloch, M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-analysis. Neuropsychopharmacology 2011, 36, 2452–2459. [Google Scholar] [CrossRef]
- Mowla, S.J.; Farhadi, H.F.; Pareek, S.; Atwal, J.K.; Morris, S.J.; Seidah, N.G.; Murphy, R.A. Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J. Biol. Chem. 2001, 276, 12660–12666. [Google Scholar] [CrossRef] [PubMed]
- Gupta, V.K.; You, Y.; Gupta, V.B.; Klistorner, A.; Graham, S.L. TrkB receptor signalling: Implications in neurodegenerative, psychiatric and proliferative disorders. Int. J. Mol. Sci. 2013, 14, 10122–10142. [Google Scholar] [CrossRef] [PubMed]
- Bath, K.G.; Schilit, A.; Lee, F.S. Stress effects on BDNF expression: Effects of age, sex, and form of stress. Neuroscience 2013, 239, 149–156. [Google Scholar] [CrossRef] [PubMed]
- Dandi, E.; Kalamari, A.; Touloumi, O.; Lagoudaki, R.; Nousiopoulou, E.; Simeonidou, C.; Spandou, E.; Tata, D.A. Beneficial effects of environmental enrichment on behavior, stress reactivity and synaptophysin/BDNF expression in hippocampus following early life stress. Int. J. Dev. Neurosci. 2018, 67, 19–32. [Google Scholar] [CrossRef]
- Kentner, A.C.; Khoury, A.; Lima Queiroz, E.; MacRae, M. Environmental enrichment rescues the effects of early life inflammation on markers of synaptic transmission and plasticity. Brain Behav. Immun. 2016, 57, 151–160. [Google Scholar] [CrossRef]
- Lommatzsch, M.; Zingler, D.; Schuhbaeck, K.; Schloetcke, K.; Zingler, C.; Schuff-Werner, P.; Virchow, J.C. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol. Aging 2005, 26, 115–123. [Google Scholar] [CrossRef]
- Tanila, H. The role of BDNF in Alzheimer’s disease. Neurobiol Dis. 2017, 97 Pt B, 114–118. [Google Scholar] [CrossRef]
- Hashimoto, K. Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions. Psychiatry Clin. Neurosci. 2010, 64, 341–357. [Google Scholar] [CrossRef] [PubMed]
- Chakrapani, S.; Eskander, N.; De Los Santos, L.A.; Omisore, B.A.; Mostafa, J.A. Neuroplasticity and the Biological Role of Brain Derived Neurotrophic Factor in the Pathophysiology and Management of Depression. Cureus 2020, 12, e11396. [Google Scholar] [CrossRef]
- Karege, F.; Perret, G.; Bondolfi, G.; Schwald, M.; Bertschy, G.; Aubry, J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002, 109, 143–148. [Google Scholar] [CrossRef] [PubMed]
- Sen, S.; Duman, R.; Sanacora, G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol. Psychiatry 2008, 64, 527–532. [Google Scholar] [CrossRef] [PubMed]
- Aydemir, C.; Yalcin, E.S.; Aksaray, S.; Kisa, C.; Yildirim, S.G.; Uzbay, T.; Goka, E. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30, 1256–1260. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Gao, R.; Yan, X.; Shu, W.; Zhang, X.; Zhang, W.; Zhang, L. Relationship between plasma brain-derived neurotrophic factor levels and neurological disorders: An investigation using Mendelian randomisation. Heliyon 2024, 10, e30415. [Google Scholar] [CrossRef] [PubMed]
- Karege, F.; Schwald, M.; Cisse, M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 2002, 328, 261–264. [Google Scholar] [CrossRef]
- Schmidt, H.D.; Duman, R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35, 2378–2391. [Google Scholar] [CrossRef]
- Zhang, J.C.; Yao, W.; Dong, C.; Yang, C.; Ren, Q.; Ma, M.; Han, M.; Hashimoto, K. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology 2015, 232, 4325–4335. [Google Scholar] [CrossRef]
- Chen, B.; Dowlatshahi, D.; MacQueen, G.M.; Wang, J.F.; Young, L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 2001, 50, 260–265. [Google Scholar] [CrossRef] [PubMed]
- Jiang, H.; Chen, S.; Li, C.; Lu, N.; Yue, Y.; Yin, Y.; Zhang, Y.; Zhi, X.; Zhang, D.; Yuan, Y. The serum protein levels of the tPA-BDNF pathway are implicated in depression and antidepressant treatment. Transl. Psychiatry 2017, 7, e1079. [Google Scholar] [CrossRef] [PubMed]
- Castrén, E.; Monteggia, L.M. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biol. Psychiatry 2021, 90, 128–136. [Google Scholar] [CrossRef] [PubMed]
- Sartori, C.R.; Vieira, A.S.; Ferrari, E.M.; Langone, F.; Tongiorgi, E.; Parada, C.A. The antidepressive effect of the physical exercise correlates with increased levels of mature BDNF, and proBDNF proteolytic cleavage-related genes, p11 and tPA. Neuroscience 2011, 180, 9–18. [Google Scholar] [CrossRef] [PubMed]
- Segawa, M.; Morinobu, S.; Matsumoto, T.; Fuchikami, M.; Yamawaki, S. Electroconvulsive seizure, but not imipramine, rapidly up-regulates pro-BDNF and t-PA, leading to mature BDNF production, in the rat hippocampus. Int. J. Neuropsychopharmacol. 2013, 16, 339–350. [Google Scholar] [CrossRef]
- Jiang, H.; Li, X.; Chen, S.; Lu, N.; Yue, Y.; Liang, J.; Zhang, Z.; Yuan, Y. Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies. Sci. Rep. 2016, 6, 30464. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Daher, J. A Potential Link between Myeloperoxidase Modified LDL, Atherosclerosis and Depression. Int. J. Mol. Sci. 2024, 25, 8805. https://doi.org/10.3390/ijms25168805
Daher J. A Potential Link between Myeloperoxidase Modified LDL, Atherosclerosis and Depression. International Journal of Molecular Sciences. 2024; 25(16):8805. https://doi.org/10.3390/ijms25168805
Chicago/Turabian StyleDaher, Jalil. 2024. "A Potential Link between Myeloperoxidase Modified LDL, Atherosclerosis and Depression" International Journal of Molecular Sciences 25, no. 16: 8805. https://doi.org/10.3390/ijms25168805